The United States has completed the study of a unique HIV vaccine
Share
The United States has completed the final phase of clinical trials of an innovative HIV vaccine. The studies have shown extraordinary effectiveness at 99 percent.
This was stated in a statement of the US Emory University.
Development of the HIV vaccine
The university's specialists, together with international partners from other science centers, developed this vaccine. Hundreds of volunteers from different age and social groups participated in the study. This guarantees the representativeness of the results.
Lenacapavir is a drug in the form of injections. It should be taken only twice a year. A key element of the tests was confirmation of its safety and effectiveness. The tests showed the ability of the vaccine to stimulate the immune system to produce specific antibodies that block the spread of the virus in the body.
What makes the vaccine special
The new approach used in the development of the vaccine allows it to be adapted to different strains of the virus, which is especially important taking into account its genetic variability. Studies have shown that two injections of lenacapavir per year reduce the risk of new HIV infection by 96%.
Scientists emphasize that this technology may also open the way to combating other chronic infections.
The leaders of the study noted that the success of the vaccine is a significant step in overcoming the global HIV/AIDS epidemic. Although the vaccine should undergo the regulatory approval process, its potential has already caused a wave of optimism among doctors and public activists.
It should be recalled that the world celebrates World HIV/AIDS Day on December 1. It is known that about 40.4 million people in total have died from this disease.
We also wrote that over five thousand new cases of HIV infection were registered in Ukraine within six months. It is known that 20-30% of these cases involve adolescents.
